Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies

Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies

Objective: Although pegylated liposomal doxorubicin (PLD) has a more favorable side-effect profile compared to doxorubicin, the FDA label for PLD includes a warning listing cardiotoxicity. Our objective was to evaluate predictors of pre- and post-treatment cardiac testing and quantify the effect of...

Full description

Saved in:
Bibliographic Details
Main Authors: Khrystyna Levytska, R. Wendel Naumann, Miranda J. Benfield, Jubilee Brown, Yovanni Casablanca, Brittany Lees, Allison M. Puechl, Erin K. Crane
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Gynecologic Oncology Reports
Subjects:
Gynecologic malignancy
Pegylated liposomal doxorubicin
Cardiotoxicity
Left ventricular ejection fraction
Echocardiogram
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578925000529
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2352578925000529

Similar Items